Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
people with obesity, in this paper
Among individuals with overweight or obesity, without DM, the trial randomly assignedassigned by chance
tirzepatide
placebo
May have lowered percentage body weight−16.3
May have lowered absolute body weight in kilograms−13.9
randomised · one subgroupthe abstract, start to end
… weight with a mean difference (MD) of -16.32% (95% CI: -18.35 to -14.29) and change in absolute body weight in kilograms (MD -13.95 kg; -18.83 to -9.07).
← favours treatmentfavours comparator →
could be chanceChange in percentage body weighttirzepatide vs placebo, in individuals with overweight or obesity, without DM
−16.32−18.4 to −14.3
Change in absolute body weight in kilogramstirzepatide vs placebo, in individuals with overweight or obesity, without DM
−13.95−18.8 to −9.07
GIP/GLP-1 & amylin agonistsBody weight & composition
GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated
unlikelylikely
1.00not counted
← favours treatmentfavours comparator →
1 / 6